Arcturus Therapeutics Holdings Inc. (ARCT) Earnings History
Annual and quarterly earnings data from 2011 to 2024
Loading earnings history...
EPS Growth Rates (CAGR)
Compound annual growth rate of diluted earnings per share
CAGR (Compound Annual Growth Rate) shows the annualized growth rate of EPS over the specified period. A higher CAGR indicates stronger earnings momentum.
Profitability Analysis
Margin trends over time
| Year | Gross Margin | Operating Margin | Net Margin |
|---|---|---|---|
| 2024 | 100.0% | -69.1% | -58.5% |
| 2023 | 100.0% | -49.6% | -18.8% |
| 2022 | 100.0% | 5.9% | 4.5% |
| 2021 | 100.0% | -1641.3% | -1648.0% |
| 2020 | -486.5% | -749.8% | -756.3% |
Download Data
Export ARCT earnings history in CSV or JSON format
Free sign-in required to download data
Arcturus Therapeutics Holdings Inc. (ARCT) Earnings Overview
As of March 1, 2026, Arcturus Therapeutics Holdings Inc. (ARCT) reported trailing twelve-month net income of -$67M, reflecting -1.7% year-over-year growth. The company earned $-2.45 per diluted share over the past four quarters, with a net profit margin of -0.6%.
Looking at the long-term picture, ARCT's historical earnings data spans multiple years. The company achieved its highest annual net income of $9M in fiscal 2022.
Arcturus Therapeutics Holdings Inc. is currently reporting a net loss, though operating performance should be evaluated in the context of growth investments and industry dynamics View revenue history →
Compared to industry peers including ALNY ($314M net income, 0.1% margin), IONS (-$381M net income, -0.4% margin), ARWR ($202M net income, -0.0% margin), ARCT has room to improve margins relative to the peer group. Compare ARCT vs ALNY →
Peer Comparison
Earnings metrics vs industry competitors
Historical Data
14 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2024 | -$81M | -172.3% | -$96M | $-3.00 | -58.5% | -69.1% |
| 2023 | -$30M | -417.9% | -$78M | $-1.12 | -18.8% | -49.6% |
| 2022 | $9M | +104.6% | $12M | $0.35 | 4.5% | 5.9% |
| 2021 | -$204M | -182.3% | -$203M | $-7.74 | -1648.0% | -1641.3% |
| 2020 | -$72M | -177.6% | -$72M | $-3.55 | -756.3% | -749.8% |
| 2019 | -$26M | -19.3% | -$26M | $-2.13 | -125.0% | -122.7% |
| 2018 | -$22M | -99.8% | -$22M | $-2.16 | -138.3% | -138.5% |
| 2017 | -$11M | +55.7% | -$10M | $-3.53 | -83.9% | -80.7% |
| 2016 | -$25M | -26.5% | -$25M | $-6.25 | -120.7% | -123.5% |
| 2015 | -$19M | +40.8% | -$20M | $-6.29 | -316.9% | -320.9% |
See ARCT's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs ARCT Undervalued?
See our Bear / Base / Bull DCF models and intrinsic value estimates.
View ValuationCompare ARCT vs AGIO
See how ARCT stacks up against sector leader Agios Pharmaceuticals, Inc..
Start ComparisonFrequently Asked Questions
Is ARCT growing earnings?
ARCT EPS of $-2.45 reflects slowing growth at -1.7%, below the 5-year CAGR of N/A. TTM net income is $-67M. Expansion rate has moderated.
What are ARCT's profit margins?
Arcturus Therapeutics Holdings Inc. net margin is -0.6%, with operating margin at -0.7%. Below-average margins reflect competitive or cost pressures.
How consistent are ARCT's earnings?
ARCT earnings data spans 2011-2024. The current earnings trend is -1.7% YoY. Historical data enables comparison across business cycles.